Leading Science
We identify science that has the potential to shake things up, approaching entrenched problems in a whole new way. We put our support behind new ideas that are going to matter, for individuals and whole societies.
Ocean Biomedical is currently developing five promising discoveries that have potential to make major changes in lung cancer care, pulmonary fibrosis, and the prevention and treatment of malaria.
We’re working on solving some of the toughest problems, for the people who need it most.
Great research science happens in small, incremental steps that require patience, tenacity, and strong backing. At each step in the process, we work to remove obstacles, allowing our scientists to focus on what they do best. From preclinical work to clinical trials and into commercial development, our experienced team smooths the road to create real progress.
focused on
progress
NON-SMALL CELL LUNG CANCER
New therapeutic antibodies for effective treatment of NSCLC and other disorders.
We are moving towards Phase 1 clinical trials of patented antibodies for the treatment of NSCLC. Our lead program, OCX-253 was chosen because it stimulates the B-Raf protooncogene while inhibiting apoptosis, NK cell accumulation and activation, LIM kinase 2, p-cofilin, the tumor suppressor PTEN, and p53. In addition, OCX-253 is a master stimulator of immune checkpoint inhibitor pathways. and plays a critical role in the pathogenesis of primary and metastatic lung cancer. Other disorders for which it shows promise include glioblastoma multiforme and metabolic disorders.
pulmonary fibrosis
A new pathway to treating pulmonary fibrosis.
We’re working on a new approach to treating Idiopathic Pulmonary Fibrosis, focusing on manipulating enzymes in ways that have been shown to have minimal system toxicity.
The background research for this asset has not yet been disseminated publicly and is currently in the pre-clinical stage, preparing for Phase 1 trials.
A new window will open.
malaria vaccine
For 500,000 children and their families each year, a malaria vaccine is life or death.
Malaria is one of the most devastating diseases in human history, and one of the most intractable diseases in modern times. It is the largest killer of children under 5 years old. And its long-term effects ruin lives and hold back societies.
We’re working to change that, with a novel approach to breaking the malarial cycle. Starting with an examination of the differences between healthy and sick children in sub-Saharan Africa, our scientists have discovered 3 distinct antibodies that can be used to create a revolutionary vaccine, and a novel treatment approach.